The financing round was led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

AI drug design

The new capital will be used for the continued development and deployment of Isomorphic Labsʼ AI drug design engine, accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating AI, engineering, drug design, and clinical talent across its sites, it states.

“This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,” says Sir Demis Hassabis, Founder and CEO. “Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This 1 capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.”

Related article

Demis Hassabis & John Jumper: Advancing AI as a scientific tool

Sir Demis Hassabis, co-founder and CEO of Google DeepMind and Isomorphic Labs, and John Jumper, Director and Senior Research Scientist at Google DeepMind, have been honored with the 2024 Nobel Prize in Chemistry for their revolutionary technology for predicting the 3D structure of proteins.

Isomorphic Labs has a strong portfolio of strategic partnerships with industry leaders like Novartis, Lilly, and Johnson & Johnson. These collaborations serve as a significant validation of Isomorphicʼs AI-first approach and the tangible value it brings to the pharmaceutical industry, the company states.